FDA questions safety, efficacy of GSK's Blenrep in multiple myeloma ahead of adcomm
The FDA is questioning whether GSK has done enough to show that Blenrep should return to the market as a second-line multiple myeloma treatment ahead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
